By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Miraculins today said that it has signed on investment firm Bloom Burton as an advisor to the company.

Bloom Burton, based in Toronto, will provide strategic and financial services, including an overview and analysis of potential opportunities, financial modeling, analysis of Miraculins' business plan, an overview and assessment of financing options, and strategic partnership opportunities, Miraculins said.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.